AdjuCor Raises € 29 Million in Series B Funding Round for its Revolutionary Heart Assist Technology that Completely Avoids Blood Contact
MUNICH, Germany, June 9, 2021 /PRNewswire-PRWeb/ --AdjuCor is developing an implantable heart assist device that, contrary to all existing heart assist devices, has the capability to assist the heart while completely avoiding the complication-laden aspect of blood contact.
- MUNICH, Germany, June 9, 2021 /PRNewswire-PRWeb/ --AdjuCor is developing an implantable heart assist device that, contrary to all existing heart assist devices, has the capability to assist the heart while completely avoiding the complication-laden aspect of blood contact.
- Securing the 29 million of this round and getting MitrAssist Holdings Limited on board are exactly what AdjuCor has been looking for to reach its goals".
- It is implanted by a heart team (cardiologist and surgeon) within a few minutes on the beating heart without sutures.
- It completely avoids blood contact and thereby any blood-related complications including strokes and bleeding an invaluable advantage that cannot be over-stated.